Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
LENZ Therapeutics, Inc. (LENZ) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $4.28, with a market capitalisation of $140.45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.21 to $50.40. This page covers its latest market performance, valuation, price trends and company information.
$140.45M | |
$4.32 | |
$50.40 | |
$4.21 | |
$4.23 | |
97.00 | |
882.84K | |
-- | |
$50.40 | |
$4.21 | |
-- | |
-- |
LENZ Therapeutics, Inc. (LENZ) is trading at $4.28 in pre-market trading as of 2026-09-16 09:01:00, up 1.16% ($0.05) from the previous close of $4.23
Pre-market trading shows how investors are pricing LENZ before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, LENZ Therapeutics, Inc. (LENZ) moved from $5.96 to $4.28, representing a decline of 28.20% ($1.68).
The stock traded between $4.21 and $5.98 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 707.00 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.2%
LENZ is currently trading at $4.28, placing it 0.2% of the way from its 52-week low of $4.21 to its 52-week high of $50.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 152 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of LENZ Therapeutics, Inc. (LENZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.